Seminars in oncology
-
Pulmonary toxicity is often encountered in patients receiving antineoplastic therapy. It may produce a wide variety of clinicopathologic syndromes. As new agents are introduced and their adverse effects recognized, clinicians should be ever vigilant about the possibility of pulmonary toxicity.
-
Seminars in oncology · Aug 1992
ReviewRationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations.
The identification of several safe and effective agents for the control of chemotherapy-induced nausea and vomiting has prompted an intensive effort to develop combination antiemetic regimens. The principal rationale for development of drug combinations is the potential for blocking different types of neurotransmittor receptors controlling the emetic process. ⋯ Preliminary data show that ondansetron can be combined with dexamethasone safely with enhanced antiemetic results. Ondansetron merits further study in combination antiemetic programs.